Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML
06/11/2020
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, discusses results from an interim analysis of the ongoing OPTIC trial, which is evaluating the association between ponatinib exposure, efficacy, and safety with response-based dose reduction in chronic-phase chronic myeloid leukemia (CML). These results were presented at the virtual 2020 ASCO Annual Meeting.